First Manhattan CO Protagonist Therapeutics, Inc Transaction History

First Manhattan CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $393,948 - $1.42 Million	55,800 New	55,800 $441,000
Q3 2018 Oct 15, 2018	SELL	$6.82 - $11.26 $874,624 - $1.44 Million	-128,244 Closed	0 $0
Q2 2018 Aug 01, 2018	SELL	$5.99 - $9.1 $97,038 - $147,420	-16,200 Reduced 11.22%	128,244 $861,000
Q1 2018 Apr 20, 2018	SELL	$8.46 - $23.08 $2.3 Million - $6.28 Million	-271,920 Reduced 65.31%	144,444 $1.24 Million
Q4 2017 Jan 22, 2018	BUY	$14.47 - $20.8 $5.78 Million - $8.32 Million	399,764 Added 2408.22%	416,364 $8.66 Million
Q3 2017 Oct 25, 2017	BUY	$10.61 - $17.98 $176,126 - $298,468	16,600	16,600 $293,000

248

56.7M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.